GlassScriptPhysician profile
Hemang Dave
NPI 1891782371
$21,602.64
in general payments reported to CMS, 2019-2025
89 companies · $2,484 in 2025
The $2,484 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,047 · 2020: $3,604 · 2021: $3,101 · 2022: $5,898 · 2023: $1,962 · 2024: $2,507 · 2025: $2,484.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,338 · Education: $615.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,338.26 |
| Education | $615.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $4,329.74 | 2021-2024 | Yescarta |
| Astrazeneca Pharmaceuticals LP | $2,465.86 | 2019-2025 | Lynparza, Enhertu, Calquence |
| Blueprint Medicines Corporation | $1,494.43 | 2020-2023 | Ayvakit |
| Novartis Pharmaceuticals Corporation | $1,433.43 | 2019-2025 | Piqray, Kisqali |
| Pfizer INC. | $884.08 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $794.24 | 2019-2025 | Keytruda, Lynparza, Welireg |
| E.R. Squibb & Sons, L.L.C. | $737.03 | 2019-2025 | Opdivo, Opdualag, Augtyro |
| Janssen Biotech, INC. | $711.90 | 2019-2025 | Erleada, Rybrevant, Darzalex |
| Eisai INC. | $546.22 | 2019-2025 | |
| Incyte Corporation | $513.41 | 2019-2025 | Pemazyre, Monjuvi, Jakafi |
| Seagen INC. | $488.16 | 2019-2023 | Padcev, Tukysa |
| Bayer Healthcare Pharmaceuticals INC. | $473.49 | 2019-2025 | |
| Genentech USA, INC. | $444.27 | 2019-2025 | Venclexta, Polivy, Lunsumio |
| Celgene Corporation | $408.81 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Astellas Pharma US INC | $381.63 | 2019-2025 | Padcev, Xtandi, Vyloy |
Show all 89 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hemang Dave listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.